NDS-ECNW

NDS-ECNW is a small private ophthalmology-focused drug development company built around intellectual property co-developed by formulation scientist Scott Karolchyk and ophthalmologist Jeffrey Liegner. The company is developing preservative-free ophthalmic anti-infective and anti-inflammatory formulations, including injectable and topical combinations intended to simplify care after cataract and LASIK procedures. Its lead asset is Trimoxi, an intraocular triamcinolone + moxifloxacin formulation for prophylaxis after cataract surgery, and the company has also described topical steroid-antibiotic eye drop combinations based on the same formulation approach. NDS-ECNW emphasizes improved patient compliance, reduced reliance on postoperative eye drops, and formulation flexibility across multiple steroid strengths and antibiotic classes. The company appears to operate as a very small, founder-led Delaware entity centered on patent ownership and ophthalmic product commercialization partnerships.